论文部分内容阅读
目的观察吉西他滨联合奈达铂治疗晚期非小细胞肺癌的疗效及毒副反应。方法23例入选病例均为Ⅲ/Ⅳ期非小细胞肺癌。给予吉西他滨1000mg/m2,静脉滴注d1,d8;奈达铂80mg/m2,静脉滴注d1。28d为1周期,4个疗程后评价疗效。结果23例患者均可评价疗效及不良反应,CR2例,PR12例,总有效率为60.9%,中位生存期11.3个月,一年生存率51.7%。主要毒副反应为骨髓抑制和消化道不良反应,无化疗相关死亡。结论吉西他滨联合奈达铂治疗晚期非小细胞肺癌疗效好,不良反应可耐受,值得临床应用。
Objective To observe the efficacy and side effects of gemcitabine combined with nedaplatin in the treatment of advanced non-small cell lung cancer. Methods Twenty-three selected cases were stage Ⅲ / Ⅳ non-small cell lung cancer. Give gemcitabine 1000mg / m2, intravenous drip d1, d8; nedaplatin 80mg / m2, d1.28d intravenous infusion for the 1 cycle, 4 after treatment evaluation. Results All the 23 patients were evaluated for efficacy and adverse reactions. CR2 and PR12 had a total effective rate of 60.9%, a median survival of 11.3 months and a one-year survival rate of 51.7%. The main toxicities were myelosuppression and gastrointestinal adverse reactions, with no chemotherapy-related deaths. Conclusion Gemcitabine combined with nedaplatin in the treatment of advanced non-small cell lung cancer has good curative effect and adverse reactions, which is worthy of clinical application.